Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 35

FDA Primary Endpoint 81.1 88.4 92.5 82.7 85.2 90.5 30 20 10 0 40 50 80 70 60 90 100 Early Clinical Response - ITT Omadacycline Moxifloxacin Delta (95% CI) -1.6 (-7.1, 3.8) Clinical Success at PTE - ITT Clinical Success at PTE - CE-PTE Delta (97.5% CI) +3.3 (-2.7, 9.3) Delta (97.5% CI) +2.0 (-3.2, 7.4) EMA Co - Primary Endpoints Omadacycline OPTIC Study Results Achieved Primary Efficacy Endpoints for Both FDA and EMA